Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC’s ‘Final Trades’

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is 

On CNBC’s “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ:NDAQ) is going higher.

On April 9, Morgan Stanley analyst Michael Cyprys upgraded Nasdaq from Equal-Weight to Overweight and raised the price target from $59 to $80.

Rob Sechan of NewEdge Wealth named Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) as his final trade.

On Tuesday, Bayer AG (OTC:BAYRY) and Alphabet’s Google Cloud announced a collaboration to develop artificial intelligence (AI) solutions to support radiologists.

Don’t forget to check out our premarket coverage here

Brian Belski of BMO Capital Markets picked Spotify Technology S.A. (NYSE:SPOT).

Spotify Technology is expected to report first-quarter earnings on April 23. Wall Street expects the company to report earnings at 81 cents per share and $3.95 billion in revenue.

Joseph M. Terranova said Teck Resources Limited (NYSE:TECK) is the way to play gold and copper.

On April 8, Benchmark analyst Nathan Martin maintained Teck Resources with a Buy and raised the price target from $50 to $52.

Stephanie Link of Hightower picked The Charles Schwab Corporation (NYSE:SCHW).

On April 9, JMP Securities analyst Devin Ryan maintained Charles Schwab with a Market Outperform and raised the price target from $77 to $80, while Morgan Stanley analyst Michael Cyprys maintained the stock with an Equal-Weight and boosted the price target from $65 to $71.

Price Action:

  • Nasdaq shares gained 2.3% to close at $63.56 on Tuesday.
  • Alphabet shares rose 1.3% to settle at $158.14 on Tuesday.
  • Spotify shares fell 2.7% to settle at $300.73 during Tuesday’s session.
  • Shares of Teck Resources gained 4.6% to close at $49.14 on Tuesday.
  • Charles Schwab shares fell 0.1% to settle at $72.28 during Tuesday’s session.

Check This Out: CarMax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Image by David Vives from Pixabay

Total
0
Shares
Related Posts
Read More

RenovoRx Announces Initial Results In Pharmacokinetic Substudy: Data On RenovoGem Supports Potential For RenovoTAMP Therapy Platform To Increase Local Gemcitabine Delivery And Decrease Side Effects Of Pancreatic Cancer Treatment

Researchers presenting four abstracts on different substudies, including the preliminary PK substudy, at the ASCO GI Cancers Symposium in San Francisco on January 19-21, 2023. RenovoRx, Inc. (NASDAQ:RNXT), a

RNXT